Dr. Chi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
44 Binney St
Rm SW331
Boston, MA 02115Phone+1 617-632-4142Fax+1 617-632-4897
Summary
- Dr. Susan Chi is a highly-qualified healthcare professional based in Boston, MA specializing in Pediatric Hematology & Oncology, with a subspecialty of Pediatric Neuro-Oncology. She initially trained in Pediatrics at Yale-New Haven Medical Center, then pursued fellowships in Pediatric Hematology/Oncology at Memeorial Sloan-Kettering Cancer Center/NY Presbyterian Cornell and Pediatric Neuro-Oncology at NYU. Since 2003, Dr. Chi has been practicing Pediatric Neuro-Oncology at the Dana-Farber Cancer Institute/Boston Children's Hospital. She has been involved in numerous experimental clinical trials and has a distinguished record of publications, including pivotal work on Atypical Teratoid Rhabdoid Tumor (ATRT) and other rare infant brain tumors. She has also contributed to the development of innovative treatments and to the establishment of new standards-of-care through the clinical trials she has led.
Education & Training
- NYU Grossman School of MedicineFellowship, Pediatric Neuro-Oncology, 2001 - 2002
- New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 1998 - 2001
- Yale-New Haven Medical CenterChief Residency, Pediatrics, 1997 - 1998
- Yale-New Haven Medical CenterResidency, Pediatrics, 1994 - 1997
- Icahn School of Medicine at Mount SinaiClass of 1994
- Princeton UniversityBA, 1990
Certifications & Licensure
- FL State Medical License 2024 - Present
- ME State Medical License 2023 - 2026
- RI State Medical License 2022 - 2026
- CT State Medical License 1997 - 2025
- MA State Medical License 2003 - 2025
- NH State Medical License 2023 - 2025
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma Start of enrollment: 2018 Sep 24
Roles: Contact
- Fimepinostat in Treating Brain Tumors in Children and Young Adults Start of enrollment: 2019 Aug 07
Roles: Contact, Principal Investigator
- Preventative Skin Care for Children Undergoing Targeted CNS Tumor Therapy Start of enrollment: 2020 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- Author Correction: Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer.Suzanne J Forrest, Hersh Gupta, Abigail Ward, Yvonne Y Li, Duong Doan
Nature Communications. 2024-08-22 - 1 citationsMolecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer.Suzanne J Forrest, Hersh Gupta, Abigail Ward, Yvonne Y Li, Duong Doan
Nature Communications. 2024-07-11 - Clinical utility of DNA methylation profiling for choroid plexus tumors.Kee Kiat Yeo, Cassie B Macrae, Bradley Gampel, Jared T Ahrendsen, Hart Lidov
Neuro-Oncology Advances. 2024-06-12
Press Mentions
- EZH2 Inhibitor Shows Promise Among Children with Certain Solid TumorsFebruary 20th, 2018
- What ‘Beans’ Taught Her Parents About Pediatric Cancer, the Need for Research, and Patient AdvocacyMarch 23rd, 2021
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: